An optimized radiosynthesis of [18F]DK222, a PET radiotracer for imaging PD-L1

IF 0.9 4区医学 Q4 BIOCHEMICAL RESEARCH METHODS

Journal of labelled compounds & radiopharmaceuticals Pub Date : 2023-01-10 DOI:10.1002/jlcr.4012

Daniel P. Holt, Dhiraj Kumar, Sridhar Nimmagadda, Robert F. Dannals

引用次数: 0

Abstract

A radiochemical synthesis of [¹⁸F]DK222, a peptide binder of programmed death ligand 1 protein, suitable for human PET studies is described, and results from validation productions are presented. The high specific activity radiotracer product is prepared as a sterile, apyrogenic solution that conforms to current Good Manufacturing Practice (cGMP) requirements. In addition, the production is extended to use a commercial synthesizer platform (General Electric FASTlab 2).

查看原文本刊更多论文

用于PD-L1成像的PET放射性示踪剂[18F]DK222的优化放射合成

描述了[18F]DK222的放射化学合成，这是一种程序性死亡配体1蛋白的肽结合物，适用于人类PET研究，并给出了验证生产的结果。高比活性放射性示踪剂产品是以无菌、无热溶液的形式制备的，符合当前良好生产规范（cGMP）的要求。此外，生产扩展到使用商业合成器平台（通用电气FASTlab 2）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of labelled compounds & radiopharmaceuticals 医学-分析化学

CiteScore

3.30

自引率

0.00%

发文量

审稿时长

1 months

期刊介绍： The Journal of Labelled Compounds and Radiopharmaceuticals publishes all aspects of research dealing with labeled compound preparation and applications of these compounds. This includes tracer methods used in medical, pharmacological, biological, biochemical and chemical research in vitro and in vivo. The Journal of Labelled Compounds and Radiopharmaceuticals devotes particular attention to biomedical research, diagnostic and therapeutic applications of radiopharmaceuticals, covering all stages of development from basic metabolic research and technological development to preclinical and clinical studies based on physically and chemically well characterized molecular structures, coordination compounds and nano-particles.